Articles

Pancreatic cancer is a difficult to treat malignancy with a high mortality rate. Patients are usually diagnosed with advanced disease, and many are not eligible for surgery. Although systemic therapy is a mainstay of treatment, there are limited options for patients with metastatic disease. We invite you to read more about some of the recent observational data on metastatic pancreatic cancer treatment patterns, patient outcomes, and costs in an effort to shed insights into real-world clinical decisions and the economic factors that influence them. Read More ›

• Brukinsa Receives Accelerated FDA Approval for Mantle-Cell Lymphoma
• Ziextenzo Third Biosimilar to Neulasta Approved for Febrile Neutropenia
• Tecentriq Approved with Chemotherapy for First-Line Treatment of Metastatic NSCLC without EGFR or ALK Mutations
• FDA Approves Calquence for Adults with CLL or SL
• Zejula Receives FDA Approval for HRD-Positive Advanced Ovarian Cancer

Read More ›

On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers. Read More ›

The ovarian cancer patients’ internal dialogue may delay a cancer diagnosis and can also overestimate the capability of chemotherapy. Read More ›

BRCA wild-type tumors are more common in women with ovarian cancer and may need higher doses of the tumor-targeting PARP inhibitor. Read More ›

The rise in the number of cancer drugs taken orally has placed a renewed focus on the importance—and challenges—of patient adherence to self-administered oral medications. Read More ›

While Medicare Part D enrollees may see their out-of-pocket expenses, deductibles, and premiums increase in 2020, protections of the drugs used in cancer treatment will remain in place. Read More ›

On December 3, 2019, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to the biopharmaceutical company Adaptimmune Therapeutics for ADP-A2M4 for the treatment of synovial sarcoma. Earlier this year, the FDA granted Orphan Drug designation to the agent for the treatment of soft tissue sarcomas. Read More ›

"Guidelines offer all possible scenarios, while pathways comprise the details. The whole objective is to facilitate quality care in all aspects of the patient interaction, including their evaluation, prevention, treatment, education, supportive care, and end-of-life. Nevertheless, there’s still some mixing of definitions across the spectrum,” said Linda D. Bosserman, MD, FACP, FASCO. Read More ›